Аннотация:The current modern chemotherapy (CHT) protocols for ALL, taking into account prognostic factors,
including assessment and monitoring of MRD, in the general group of patients (pts) allow achieving complete remission
(CR) in 80–90% cases. In adult pts with primary B-cell ALL CR rates of 80–90% are routinely achieved with standard
multidrug chemotherapy, however, 5-year disease free survival is only around 40%. The prognosis of pts with relapses or
refractory disease are dismal, 5-y overall survival after treatment failure is about 10%. Therapy of r/r B-ALL remains a
challenge. Intensification of CHT has not been successful secondary to high toxicity rates. Each subsequent line of
therapy reduces the response rate and the duration of the achieved remission, which complicates the sequential
implementation of allogeneic hematopoietic cell transplantation (alloHCT). Novel targeted therapies have been shown to
improve outcomes in pts with adult B-ALL. Inotuzumab ozogamicin (InO), a new antibody–drug conjugate, has shown
significant activity in adult patients with r/r B-ALL.